Cytarabine (intrathecal)

DRUG2 trials

Sponsors

Novartis Pharmaceuticals, Therapeutic Advances in Childhood Leukemia Consortium

Conditions

Acute Lymphoblastic LeukemiaLeukemia, Lymphoblastic, Acute, Philadelphia-PositiveLeukemia, Myeloid, AcutePhiladelphia Chromosome Positive Acute Lymphoblastic Leukemia

Phase 1

Safety and Efficacy of Asciminib in Pediatrics and Young Adults With Relapse/Refractory (r/r) Philadelphia Positive (Ph+) or ABL-class Ph-like Acute Lymphoblastic Leukemia (ALL)

Not yet recruitingNCT07387926

Novartis PharmaceuticalsAcute Lymphoblastic Leukemia, Leukemia, Lymphoblastic, Acute, Philadelphia-Positive, Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia

Start: 2026-07-30End: 2036-06-18Target: 50Updated: 2026-05-19

Phase 2

Phase 2 Trial of Revumenib Plus FLA Chemotherapy for Children With Relapsed or Refractory NUP98-rearranged AML."

Not yet recruitingNCT07686107

Therapeutic Advances in Childhood Leukemia ConsortiumLeukemia, Myeloid, Acute

Start: 2026-08-31End: 2030-12-31Target: 24Updated: 2026-07-07